Data Sharing Statement		
Article Info	http://dx.doi.org/10.21037/atm-20-5359	
Item	**Question**	**Authors' Response (place "-" if not applicable)**
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The therapeutic outcomes data in particular will be shared. This study demonstrated that atenolol was effective in the treatment of IHs. Compared to propranolol, atenolol seems to have a similar effect on IHs. Furthermore, atenolol seems to be less frequently associated with potentially life-threatening side effects.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Four years within the publication date, since randomized controlled clinical trial will be conducted to prove the equal efficacy and better tolerance of atenolol compared with propranolol.
7	To whom will you share the data?	Oral and maxillofacial surgeons and pediatricians who are interested in studies of infantile hemangioma.
8	For what type of analysis or purpose?	For analysis to evaluate the safety of oral atenolol in infantile hemangioma patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: davidzhengjw@hotmail.com.

10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.